Pharmacokinetics and Bioequivalence of Rivaroxaban Tablet in Healthy Chinese Volunteers
Status:
Completed
Trial end date:
2019-09-20
Target enrollment:
Participant gender:
Summary
The study was designed as a single-site, randomized, open-label, four-period complete and
replicate crossover. A single oral dose of 20 mg rivaroxaban tablet (test) and
Xarelto®(reference) was given to the 72 healthy Chinese adult volunteers, with 36 in a
fasting state and 36 receiving a high-fat diet.